Novartis to get rights to HCV compound

Thursday 23 February 2012

Novartis has agreed to pay privately-owned Enanta Pharmaceuticals Inc $34 million upfront, plus potential milestones of $406 million, for exclusive rights to a compound to treat hepatitis C. The compound is poised to enter clinical development.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States